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Abstract 
Background: Breast cancer is the most common invasive cancer with high mortality in 
women all around the world. The present evidence shows that younger patients have poor 
survival. Thus, the aim of this study was to compare the pathologic characteristics of 
breast cancer in women younger than 40 years compared with older. 
Methods: This is a cross-sectional study which contains 681 patients with a confirmed 
diagnosis of breast cancer, who referred to Babolsar Shahid Rajaei Hospital as a referral 
cancer therapeutic center in the North of Iran. The data included age, residence area, 
occupation, location, histopathologic characteristics of the tumor, TNM classification and 
staging. 
Results: The mean age (SD) of patients was 49.7 (11.9) years, of which 19.5% were under 
40. Ductal carcinoma was the most common histopathologic type (90.0%) but patients at a 
younger age had a higher incidence of lobular and other rare carcinoma compared to the 
older ones (P=0.04). The younger had a greater tumor size (P=0.01), lymphatic node 
involvement (P=0.04) and higher staging (P=0.004). The younger age was not associated 
with positive estrogen/progesterone receptors. 
Conclusion: These findings indicated more aggressive tumor characteristics and serious 
breast cancer in women less than 40 years compared with older ones. 
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Breast cancer is a major public health problem and the most common aggressive 
cancer in women with a high rate of mortality worldwide (1-4). It was estimated that 1.8 
million new cases of breast cancer were diagnosed in 2015 all over the world (5). Also, the 
American Cancer Society reported that 231840 new cases of invasive and 60290 
nonaggressive breast tumor were diagnosed in American women in 2015 (6). Annually, 
roughly 40290 American women die from breast cancer that is attributed to 3% of all 
deaths and women living in the United States has 12.3% lifetime risk i.e. 1 in 8 women 
suffers from breast cancer in her life span (6). According to the International Agency of 
Cancer Research, about 10980 patients of new breast cancer were diagnosed in the Islamic 
Republic of Iran in 2015 (5). In fact, breast cancer includes 18.9% of all cases of cancer 
incidence among Iranian women. A perspective view of the demographic characteristic of 
breast cancer incidence in Iranian women is that the patients’ age at diagnosis is, on 
average, about 10 years younger than western counterparts (7). The multiple risk factors 
such as family history, reproductive behaviors, lifestyle-related factors like obesity, 
smoking, low physical activity and exposure to radiation, stress, and anxiety were reported 
as determinants of its incidence (7-10). 
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Its prognosis depends on the type of therapeutic agents 
received, staging and pathological characteristics of tumor 
(tumor size, node involvement and presence of metastasis 
(TNM) and the demographic profiles that may have all 
predicted the survival changing in lifestyles and reproductive 
behaviors in recent decades (7, 9, 10 and prognosis (11, 12). 
Despite the low incidence of breast cancer in younger 
women, delay in diagnosis is possible; on the other hand, the 
poor prognosis in younger patients raised the question 
whether this is designated by the pathological characteristics 
of tumor or not. In spite of changes in lifestyles and 
reproductive behaviors in recent decades (7, 9, 10) which has 
led to an increase in the incidence of breast cancer in Iranian 
women particularly in the North, the South of Caspian sea, 
the comparative data of pathologic characteristics of younger 
and older women is sparse in this region. Thus, the objective 
of this study was to compare the pathologic findings between 
women younger than 40 years and older. This new 
information would help public health managers for 
prevention, screening, and promotion of survival and also 
would enhance the knowledge of the general population in 
promotion of self- care behaviors.  
 
 
Methods 
This cross-sectional study was conducted in Babolsar 
Shahid Rajaie Hospital, as a referral center for cancer radio-
chemotherapy in the North of Iran. A total of 681 patients 
with pathologically confirmed breast cancer were entered in 
the study that was treated from March 2005 to December 
2014. Male breast cancer patients and patients who had no 
pathologic reports and those which their charts were 
inaccessible were excluded from the study. Through 
patients’ names and their charts’ numbers, their hospital 
charts were extracted. The demographic characteristics, 
clinical and histopathological variables were also extracted 
from patients’ charts and the study checklists were fulfilled. 
The data included age, residence area, the presence of 
estrogen and progesterone receptors, type of tumors 
histopathology, breast location, tumor size, nodal 
involvement, the presence of metastasis at diagnosis were 
collected. In all records, T, N, M stages were determined 
according to TNM classification. Estrogen and progesterone 
receptors (ER and PR) expression were assessed by enzyme 
immuno-histopatho chemistry immunoassay as positive or 
negative. The stage was calculated based on the clinical 
definition of TNM classification. The protocol of this study 
was approved by the Ethics Committee of Babol University 
of Medical Sciences (MUBABOL.REC.1394.225). 
Statistical Analysis: We used SPSS software Version 18.0 
for data analysis. The patients were categorized into two 
groups (less than 40 and ≥40 years). The descriptive 
statistics were presented as mean±SD for quantitative data 
and the frequency and percentage by the cross table for 
categorical data. The distribution of the size of the tumor, 
nodal involvement and the presence of metastasis and 
staging and histopathology type were compared between two 
groups of ages. The Chi-square test was performed to 
determine the association between pathologic findings and 
age group and the p-values less than 0.05 were considered as 
significant level. In addition, the logistic regression model 
was applied to estimate the odds ratio and its 95% 
confidence interval of younger age (<40 years) versus older 
in association with tumor characteristics as outcome 
variables. In the logistic regression model, the presence of 
tumor size of T2 or greater, the presence of nodal 
involvement, the presence of metastasis, the stage of 2 or 
higher, PR positive and ER positive were considered as 
outcomes of interest. 
 
 
Results 
The mean age (±SD) of patients was 49.7±11.9 years 
(ranged from 17 to 95 years). The majority of patients 
(80.5%) was ≥40 years versus 19.5% at age <40 years. The 
most common prevalent age group was 40-49 years (33.0%). 
Most patients were residents of the urban area (65.6%) and 
housewives (87.3%) and only 12.6% were either working or 
retired.  
About 46.7% of cases, the breast malignancy was located 
on the right side of the breast and 51.2% on the left side and 
in only 2.0% of cases, malignancy was bilateral. Table 1 
shows that among 526 women with known status of 
hormone receptors, older women (≥40 years) compared with 
younger (<40 years) had a greater proportion of positive 
progesterone receptor (74.1% versus 69.6%), but the 
difference did not appear to be significant (P=0.63). A 
similar proportion of women had positive estrogen receptor 
in older age compared with younger (74.1% versus 68.6%, 
P=0.26). Table 2 indicates the distribution of TNM 
classification and histological type according to age group. 
Ductal carcinoma was the most common prevalent 
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histological type (90.0%) while the relative frequency of 
lobular carcinoma was about 5.9% and the other rare breast 
malignancies were 4.1%. Lobular carcinoma and other rare 
histological types such as medullary, lymphoma, angiosarcoma 
but not ductal carcinoma, were more significantly common 
in younger age compared with older women (P=0.04). In 
both age groups, tumor size of T2 (55%) was the most 
frequent and overall, younger women had a greater tumor 
size than older (P=0.01). Moreover, younger women had a 
significantly greater proportion of nodal involvement 
(P=0.04) but the association between age and the presence of 
metastasis did not appear to be significant (P=0.50).  
Table 1. The positive and negative progesterone (PR) and 
estrogen (ER) receptors in breast cancer patients with 
age groups 
Hormone 
receptors 
All
*
 
N (%) 
<40 y 
N (%) 
≥40 y 
N (%) 
P-
value 
PR+ 
PR- 
385(73.2) 
141(26.8) 
71(69.6 
31(35.4) 
314(74.1) 
110(25.9) 
0.63 
ER+ 
ER- 
384(73.0) 
142(27.0) 
70 (68.6) 
32(31.4) 
314(74.1) 
110(25.9) 
0.26 
All 526 (100) 102(100) 424 (100)  
* In 155 patients’ charts, the data of hormone receptors were unknown. 
 
Table 2. The tumor characteristics (TNM classification) 
and histopathology of breast cancer patients with respect 
to age groups. 
TNM Classification& 
Histopathology 
All 
N (%) 
<40 y 
N (%) 
≥40 y 
N (%) 
P-
value 
Tumor size T1 
T2 
T3 
 T4 
149(23.3) 
352(55.1) 
113(17.7) 
25 (3.9) 
17(13.9) 
72(59.0) 
30(24.6) 
3  (2.5) 
132(25.5) 
280(54.2) 
83 (16.1) 
22 (4.3) 
0.01 
Node 
Involvement 
N0 
N1 
N2  
N3 
271(42.5) 
256(40.2) 
85 (13.3) 
25 (3.9) 
42(34.3) 
57(46.4) 
21(17.2) 
2 (1.6) 
226(42.5) 
199(38.6) 
64 (12.4) 
23 (4.5) 
0.04 
Metastasis M0 
M1 
588(91.3) 
56 (8.7) 
116(92.8) 
9 (7.2) 
472(90.9) 
47 (9.1) 
0.50 
Histopathology Ductal 
Lobular 
Others* 
591 (90) 
39 (5.9) 
27 (4.1) 
108(84.4) 
8 (6.3) 
12 (9.4) 
483(91.3) 
31 (5.9) 
15 (2.8) 
0.04 
*Medullary, lymphoma, angiosarcoma 
Regarding TNM classification, on the 633 women with 
known status of all TNM characteristics, the clinical staging 
was determined and table 3 shows  46.4% of patients (21.7% 
versus 28.2% in older and younger respectively) were 
diagnosed at stage III (IIIA, IIIB, and IIIC) overall. Only 
5.8% of younger and 18.2% of older women were diagnosed 
at stage I. The more advanced stage was observed in younger 
women and this was statistically significant (P=0.004). 
Moreover, in our findings, lobular carcinoma and other rare 
carcinoma had a greater chance of being metastatic (P=0.04) 
but the association of histological type with stage and the 
presence of estrogen receptor was not observed with 
statistical significance (P=0.10, P=0.07, respectively). Table 
4 presents that odds ratio and its 95% confidence interval of 
younger women versus older in association with tumor 
characteristics. A significant association was found in 
relation with the stage of ≥ 2 (OR=3.63, 95%CI: 1.64-8.02), 
tumor size of≥T2 (2.13, 95%CI: 1.23-3.68) and nodal 
involvement (OR=1.55, 95%CI: 1.03-2.35), while other 
characteristics did not appear to be significant. 
Table 3. The staging status of breast cancer patients 
according to age groups 
Stage All
*
 
N (%) 
<40 y 
N (%) 
≥40 y 
N (%) 
P-value 
I 100 (15.8) 6 (5.8) 93 (18.2)  
0.004 IIA 56 (8.8) 35 (28.9) 127 (24.8) 
IIB 162 (25.6) 36 (29.8) 134 (26.2) 
IIIA 10  (26.9) 29 (24.0) 72 (14.1) 
IIIB 101 (16.0) 3 (2.5) 19 (3.7) 
IIIC 22 (3.5) 2 (1.7) 20 (3.9) 
IV 22 (3.5) 9 (7.4) 47 (9.2) 
All 633 (100) 121 (100) 512 (100) 
* In 48 cases, the stage was not determined because of missing data of TNM 
status. 
Table 4. The odds ratio (OR) and its 95% confidence 
interval (CI) of younger age versus older in association 
with tumor characteristics as outcome variables  
Tumor characteristics  OR 
(95% CI) 
P-
value 
Tumor size ≥T2 vs. T1 2.13 
(1.23, 3.68) 
0.007 
Nodal involvement vs. not 1.55 
(1.03, 2.35) 
0.035 
Stage≥2 vs. Stage 1 3.62 
(1.64, 8.02) 
0.002 
Presence of metastasis vs. not 0.80 
(0.38, 1.67) 
0.50 
PR
+
 vs. PR
-
 0.80 
(0.50, 1.29) 
0.36 
ER
+ 
vs. ER
-
 0.76 
(0.47, 1.21) 
0.24 
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Discussion 
Our findings show that the mean age of breast cancer 
incidence was 49.7 years and 19.5% were diagnosed at age 
less than 40 and the most prevalent age group was 40-49 
years. This issue is in contrast to the patients in the United 
States with developed breast cancer, which their mean age 
was 61 years (6). In the study by Alieldin et al (14) and also 
Abdullateef et al. (15) reported among Egyptian and  Iraqi 
women, respectively, the most common age group was 40-49 
years of which is rather similar to our findings, but in the 
study by Colleoni et al., only 2% of patients were at age <40 
years in European women (16). Additionally, women <=40 
years comprise roughly 5% of all new cases in the United 
States (17). While our findings and other reports from 
Iranian female breast cancer (7, 18) indicate that the 
experience of Iranian women was about one decade lower 
than western counterparts at the time of diagnosis. 
In the present study, ductal carcinoma was the most 
prevalent histological type. This is in accordance with other 
reports in different regions of Iran (7). Abdollateef et al also 
found a higher proportion of ductal carcinoma (98%) than 
ours and a very low prevalence of lobular carcinoma (15). 
While in our findings, the proportion of lobular carcinoma 
and other rare breast malignancy were more common in 
younger age. In contrast, others reported a greater proportion 
of lobular carcinoma in older age (18, 19). The differences 
were mainly explained by ethnic variation and the 
differences in socioeconomic characteristics and nutritional 
behaviors. 
In our study, the negative estrogen receptor was tended to 
be greater in younger women but the difference was not 
statistically significant. This might be due to the lack of 
sufficient sample size because of some missing data on 
hormone receptor status in our study samples that preclude 
achieving a reasonable statistical power for detection of its 
association. However, some reports showed that the presence 
of negative estrogen receptor in younger women was 
significantly greater than the older ones (19, 20). 
Considering the fact that the expression of hormone 
receptors would have a favorable response to hormonal 
therapy (6), therefore, this would be an evidence for poor 
prognosis of disease in younger patients. Thus, the younger 
patients with a high rate of negative estrogen and 
progesterone receptors, need aggressive therapeutic agents 
such as chemotherapy instead of hormonal therapy alone 
(20). In our findings, according to tumor size, overall, the 
highest proportion of patients were at T2 (2-5 cm) in TNM 
classification, while the younger patients had a greater 
experience with a higher tumor size. This result was also 
inconsistent with other reports (18, 21). It seems the 
probability of untouchable tumor with the size of 3-4 cm 
increases in younger ones. This untouchable size by patients 
or nurses would help subsequent follow up for further 
workup for diagnosis. But the higher prevalence of greater 
tumor size in younger women is as an indicator of increased 
risk of malignancy (19). Additionally, in our result, the 
proportion of nodal involvement was greater significantly in 
younger. This finding also is in accordance with other 
reports (19, 20). This similarity of results highlights an 
evidence for poor prognosis of breast cancer for younger 
women. 
 In the present study, the younger women had 
significantly higher stage at diagnosis than older ones and a 
few younger patients were diagnosed in stage I compared to 
the older ones. In both groups of age, the majority of patients 
were diagnosed at stage II and III. Besides, this result is 
rather similar to those reported in other studies (15, 20, 22). 
Nonetheless, in our finding, a smaller proportion of patients 
were diagnosed at stage I than other studies. This is perhaps 
because of lack of mass screening program among Iranian 
women (23). This study may have some limitations for 
generalizability of results. Because it is based on existing 
data in hospital charts. Some hospital charts have no data on 
pathologic findings and hormone receptor status and a few 
charts were inaccessible. This may preclude generalizability 
of findings. Nevertheless, the patients without pathologic 
reports that were excluded from the study and those who had 
this report to meet the inclusion criteria for recruitment 
might not differ in terms of pathologic characteristics and 
severity of diseases. This may reasonably assume to occur 
non-differential pattern since there was no systematic 
intention for chart selection. In addition, the relatively large 
sample size included in the study minimizes the sampling 
variations and random errors on the estimate of proportion 
indexes to achieve a desired power of statistical test in the 
comparison between two groups under study. 
In conclusion the results indicate that breast cancer has a 
high incidence among Iranian women less than 40 years old 
and thus, the mean age of its incidence is a decade lower 
compared with western counterparts. The younger patients 
have a higher tumor size and greater nodal involvement than 
older 40 years and thus their diagnosis occurs at a higher 
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stage in younger age. Therefore, younger women were 
involved with more aggressive tumor and thus poor 
prognosis. 
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